Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial-Reference-Cited by-同舟云学术

Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial

Published:2023-05 Issue:5 Volume:37 Page:108472
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Gullaksen Søren^ORCID,Vernstrøm Liv^ORCID,Sørensen Steffen Skovgaard,Funck Kristian Løkke^ORCID,Petersen Line,Bek Toke^ORCID,Poulsen Per Løgstrup^ORCID,Laugesen Esben^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference35 articles.

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group;Lancet,1998

2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus;Nathan;N Engl J Med,1993

3. Diabetic retinopathy;Cheung;Lancet,2010

4. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes;Marso;N Engl J Med,2016

5. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial;Diabetologia;2024-07-30

2. Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial;Diabetes, Obesity and Metabolism;2024-01-19

3. GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms;Journal of Diabetes and its Complications;2023-08